Cancer Management and Research最新文献

{"title":"Clinical Value of Low-Dose Spiral CT Combined with Serum CEA in the Differential Diagnosis of Early Lung Cancer.","authors":"Jianguo Jin, Liping Wu","doi":"10.2147/CMAR.S516235","DOIUrl":"10.2147/CMAR.S516235","url":null,"abstract":"<p><strong>Purpose: </strong>Early detection of lung cancer is critical to improving prognosis, yet current screening methods such as low-dose spiral CT and serum CEA each have diagnostic limitations. This study aims to analyze the clinical value of low-dose spiral CT combined with serum CEA in the differential diagnosis of early lung cancer.</p><p><strong>Materials and methods: </strong>In this retrospective study, 62 patients diagnosed with early lung cancer in our hospital from April 2022 to October 2023 were selected as the case group, and 50 patients diagnosed with benign pulmonary lesions during the same period were selected as the control group. Data from low-dose spiral CT and serum CEA levels were compared. The efficacy of low-dose spiral CT alone, serum CEA alone, and the combination of both in discriminating early lung cancer was assessed using ROC curves.</p><p><strong>Results: </strong>Low-dose spiral CT showed a sensitivity of 77.42%, a specificity of 94.00%, and an AUC of 0.8571 (95% CI: 0.7832-0.9310) in detecting early lung cancer. Serum CEA levels were significantly higher in the case group compared to the control group (P<0.05). Serum CEA yielded an AUC of 0.8661 (95% CI: 0.7964-0.9359) in distinguishing early lung cancer (P<0.0001). Low-dose spiral CT combined with serum CEA detection achieved an AUC of 0.9137 (95% CI: 0.8624-0.9650), significantly increasing the early lung cancer detection rate from 82.26% to 95.16% (P<0.05).</p><p><strong>Conclusion: </strong>Patients with early lung cancer show distinct alterations in low-dose spiral CT signs, and their serum CEA levels demonstrate a notable increase compared with those with benign pulmonary lesions. The combination of low-dose spiral CT with serum CEA can be considered in the discrimination of early lung cancer, which can markedly enhance the positive detection rate while maintaining a minimal rise in false-positive rates.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1421-1432"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Chain Mediating Role of Hope and Posttraumatic Growth Between Social Support and Psychological Distress Among Lung Cancer Patients.","authors":"Jin-Gui Huang, Chen-Han Xu, Yu-Mei Shi, Juan Jiang, Feng-Mei Huang, Ling-Li Xu","doi":"10.2147/CMAR.S522791","DOIUrl":"10.2147/CMAR.S522791","url":null,"abstract":"<p><strong>Purpose: </strong>This research was designed to explore whether hope and posttraumatic growth (PTG) played a mediating role between social support and psychological distress in patients diagnosed with lung cancer.</p><p><strong>Patients and methods: </strong>A hospital-based cross-sectional study was carried out on 502 lung cancer patients. From September 2023 to April 2024, participants were recruited via convenience sampling from one tertiary cancer hospital and two tertiary general hospitals in Chongqing, China. Patients completed questionnaires on demographics, medical information, Distress thermometer, Perceived Social Support Scale, Posttraumatic Growth Inventory, and Herth Hope Index. Statistical analyses included Pearson's chi-squared test or Fisher's exact test for differences in patient characteristics by psychological distress level. Pearson correlation analysis explored relationships among variables. Bootstrapping in structural equation modeling (SEM) evaluated structural paths, and multi-group SEM analysis tested the moderating effect of gender.</p><p><strong>Results: </strong>43.6% (219/502) of lung cancer patients experience psychological distress. After controlling for cancer stage and distant metastasis, the results suggested that social support had a negative direct effect on psychological distress. In addition, social support could also influence psychological distress via three pathways: (1) the mediating effect of hope, (2) the mediating effect of PTG, and (3) the serial mediating effect of hope and PTG. The indirect effect of the three intermediary paths accounted for 72.7% of the total effect. Gender moderated the effect of social support on PTG (<i>β</i> = -0.286, <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>This study found that lung cancer patients exhibit high levels of psychological distress. Social support directly impacts psychological distress and acts through multiple pathways: the mediating effects of hope and PTG, as well as their serial mediation. These findings deepen our understanding of how social support affects psychological distress in lung cancer patients and its underlying mechanisms, providing empirical support for developing interventions to alleviate distress.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1399-1419"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.","authors":"Yuan Ye, Shuhong Li, Zhi Guo, Lijun Zhao, Huanhuan Zhou, Nan Zhong, Mingxin He, Yu J Cao, Liqiong Liu","doi":"10.2147/CMAR.S521944","DOIUrl":"10.2147/CMAR.S521944","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of novel loop-structure-based CD19/CD22 dual-target chimeric antigen receptor T-cell (CD19/CD22 BS LoopCAR-T) therapy in high-risk diffuse large B-cell lymphoma (DLBCL) presenting with hemophagocytic lymphohistiocytosis (HLH).</p><p><strong>Methods: </strong>We analyzed the clinical data of a high-risk DLBCL patient presenting with HLH treated with CD19/CD22 BS LoopCAR-T at the Affiliated Nanshan Hospital of Shenzhen University in December 2023.</p><p><strong>Results: </strong>The patient, a 59-year-old female, was diagnosed with myelodysplastic syndromes with multilineage dysplasia in October 2022. Following six cycles of azacitidine treatment, her bone marrow and hemogram returned to normal, and the disease was stable In August 2023, she presented with recurrent fever for over a month and was diagnosed with high-risk DLBCL stage IVB presenting with HLH. After receiving the HLH-1994 protocol followed by one cycle each of R-CHOP and R-DA-EPOCH regimens, the patient underwent infusion of CD19/CD22 BS LoopCAR-T cells at a dose of 1.73×10⁸ cells. She experienced a rapid response, developing grade 1 cytokine release syndrome (CRS) and no immune effector cell-associated HLH-like syndrome (IEC-HS), and achieved disease stabilization following aggressive treatment. Bone marrow and peripheral blood flow cytometry at one and three months post-CAR-T therapy showed complete remission (CR). PET-CT at three months post-CAR-T therapy also indicated CR. The patient was followed up until April 2025, and the disease-free survival time after CAR-T treatment exceeded 16 months.</p><p><strong>Conclusion: </strong>The novel CD19/CD22 BS LoopCAR-T therapy is safe and effective in treating high-risk DLBCL patients presenting with HLH.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1389-1398"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.","authors":"Fengying Gong, Yunshui Cheng, Yongchun Li, Qin Fan, Rongmei Qu, Tingyu Fan, Ying Lv, Jingxing Dai","doi":"10.2147/CMAR.S529467","DOIUrl":"10.2147/CMAR.S529467","url":null,"abstract":"<p><p>Malignant pleural effusion (MPE) is characterized by the accumulation of fluid in the chest cavity, secondary to metastasis from a primary pleural tumor or malignant neoplasms originating from other anatomical sites. MPE is associated with a poor prognosis. Consequently, timely and effective prevention and management of MPE are critical. In Western medicine, the treatment of MPE primarily involves procedures such as surgical puncture for drainage, pleural fixation, chemotherapy, and targeted therapy. In contrast, traditional Chinese medicine (TCM) offers therapeutic modalities including oral decoctions, thoracic perfusion with herbal injections, topical applications of medicinal pastes, and acupoint therapies. The TCM approaches have demonstrated satisfactory clinical outcomes. Advances in the study of TCM for managing MPE in lung tumors are expected to yield a wealth of therapeutic strategies, facilitating the development of more optimized clinical treatments.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1377-1388"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory and Nutritional Biomarker in Different Subtypes of Early Stage Diffuse Large B-Cell Lymphoma: Towards a Diagnostic Model.","authors":"Amaylia Oehadian, Stephanie Victoria Gunadi, Lusi Mersiana, Evan Susandi, Indra Wijaya, Januar Wibawa Martha, Rudi Supriyadi, Delita Prihatni","doi":"10.2147/CMAR.S527855","DOIUrl":"10.2147/CMAR.S527855","url":null,"abstract":"<p><strong>Background: </strong>Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy with distinct Germinal Center B-Cell Like (GCB) and non-GCB subtypes. Accurate subtyping is crucial due to differences in prognosis and treatment response. While gene expression profiling is the gold standard, it is often unavailable in low-resource settings. Inflammatory and nutritional biomarkers such as Systemic Immune-Inflammation Index (SII), Prognostic Nutritional Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI) offer a practical alternative. This study aims to evaluate their diagnostic potential in early-stage DLBCL subtypes.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted on 60 early stage DLBCL patients (30 GCB, 30 non-GCB) at Dr Hasan Sadikin General Hospital Bandung. Clinical characteristics, hematological parameters, and inflammation-based indices (SII, PNI, and ALI) were evaluated. Differences between subtypes were analyzed using the Mann-Whitney <i>U</i>-test, and Receiver Operating Characteristic (ROC) analysis was used to determine diagnostic performance.</p><p><strong>Results: </strong>The median SII was significantly higher in non-GCB compared with GCB (982,575; IQR: 609,112-2,239,917 vs 575,598; IQR: 454,578-886,426, p = 0.014). Conversely, PNI was higher in GCB compared to non-GCB group (49.18; IQR: 46.38-56.38 vs 45.96; IQR 40.05-52.28, p = 0.011). ALI values were also higher in the GCB than non-GCB (44.14; IQR: 27.69-67.18 vs 24.51; IQR: 14.34-42.47,p=0.003). ROC analysis revealed that ALI had the highest diagnostic accuracy (AUC = 0.724; 95% CI: 0.593-0.831), followed by SII (AUC = 0.685, 95% CI: 0.552-0.799) and PNI (AUC = 0.691 95% CI: 0.558-0.804). Optimal cut-off values were ≤1,234,133 for SII, >43.27 for PNI, and >27.41 for ALI. ALI demonstrated the best balance between sensitivity (76.7%) and specificity (63.3%), making it the most reliable marker for distinguishing DLBCL subtypes.</p><p><strong>Conclusion: </strong>SII, PNI, and ALI differ significantly between DLBCL subtypes. These findings suggest that integrating these indices into a diagnostic model could enhance risk stratification and guide therapeutic decision-making in DLBCL. Further studies with larger cohorts are warranted to validate these findings.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1361-1367"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of Refractory Hypertension Following Radical Nephrectomy for Renal Cell Carcinoma: A Case Report from Somalia in Resource Limit Setting.","authors":"Rahmo Mohamed Ali, Abdullahi Abdirahman Omar, Ismail A Ali","doi":"10.2147/CMAR.S530092","DOIUrl":"10.2147/CMAR.S530092","url":null,"abstract":"<p><strong>Introduction: </strong>Renal cell carcinoma (RCC) is among the most prevalent kidney malignancies and is characterized by a variety of histological subtypes, with clear cell RCC being the most common subtype. Hypertension may occur as a paraneoplastic manifestation, although the resolution of refractory hypertension following radical nephrectomy remains an uncommon event. To our knowledge, this is the first documented case from a resource-limited setting in which refractory hypertension resolved completely following radical nephrectomy for RCC, underscoring unique diagnostic and therapeutic challenges in such environments.</p><p><strong>Case presentation: </strong>A 56-year-old male presented with severe uncontrolled hypertension accompanied by persistent headaches and palpitations and was unresponsive to standard anti-hypertensive therapy. Clinical examination revealed a palpable mass in the right flank. Abdominal computed tomography revealed a large, heterogeneous mass (approximately 10 cm) occupying the hepatorenal space, which was initially suggestive of pheochromocytoma. Due to limited diagnostic resources, confirmatory biochemical testing was unavailable. The patient underwent radical nephrectomy and histopathology confirmed clear cell RCC (WHO/ISUP grade 2). The patient's hypertension resolved completely postoperatively, with subsequent follow-ups demonstrating stable blood pressure and no metastatic disease.</p><p><strong>Conclusion: </strong>This case emphasizes an uncommon presentation of refractory hypertension linked directly to RCC that resolved after radical nephrectomy. This case underscores the importance of considering RCC as a differential diagnosis for refractory hypertension, particularly in resource-limited settings where advanced diagnostics and recent surgical are unavailable.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1369-1375"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Deep Learning and Radiomics in Differentiating Papillary Thyroid Microcarcinoma from Papillary Thyroid Carcinoma with Ultrasound Images.","authors":"Bing Yu, Huijuan He, Qiao Zheng, Yao Ai, Xianwen Yu, Sunjun Li, Ji Zhang, Juebin Jin, Xiance Jin, Wenliang Yu","doi":"10.2147/CMAR.S507943","DOIUrl":"10.2147/CMAR.S507943","url":null,"abstract":"<p><strong>Purpose: </strong>The feasibility and accuracy of ultrasound-based radiomics, deep learning, and combined deep learning radiomics models were investigated in the differentiation of papillary thyroid carcinoma and papillary thyroid microcarcinoma to decrease the risk of overtreatment of papillary thyroid microcarcinoma.</p><p><strong>Methods: </strong>A total of 549 patients with confirmed 180 papillary thyroid carcinoma and 436 papillary thyroid microcarcinoma nodules from Hospital One were enrolled and randomly divided into training and validation cohorts at a ratio of 8:2 with 56 patients left as independent testing set 1. Fifty patients from Hospital Two were enrolled as independent testing set 2. Radiomics signature and five deep learning networks, such as visual geometry group 13 (VGG13), VGG16, VGG19, AlexNet, and EfficientNet, were generated for papillary thyroid carcinoma and papillary thyroid microcarcinoma differentiation. Combined deep learning and radiomics models were constructed to further improve the differentiation ability.</p><p><strong>Results: </strong>An area under curves of 0.826 and 0.822 was achieved with radiomics model for papillary thyroid carcinoma and papillary thyroid microcarcinoma differentiation in the independent testing set 1 and set 2, respectively. VGG19 achieved the best area under curves of 0.890 and EfficientNet achieved the best accuracy of 0.867. The best accuracy and area under curves of 0.904, 0.900, and 0.931, 0.946 were achieved with the combination of VGG + radiomics (R_V_Combined) and EffiecientNet + radiomics (R_E_Combined) in the independent testing set 1 and set 2, respectively.</p><p><strong>Conclusion: </strong>Deep learning and radiomics combination models are promising in the noninvasively preoperative differentiation of papillary thyroid microcarcinoma and papillary thyroid carcinoma to decrease the overtreatment of patients with papillary thyroid microcarcinoma and to minimize the complications caused by overtreatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1339-1349"},"PeriodicalIF":2.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of Combined Systemic Immune-Inflammatory Index (SII) and Prognostic Nutritional Index (PNI) in Solid Tumor.","authors":"Yan Zhang, Min Tang, Qian-Hui Gu, Li-Na Zhou, Min-Bin Chen","doi":"10.2147/CMAR.S523419","DOIUrl":"10.2147/CMAR.S523419","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and nutrition status were the essential factors for cancer initiation and progression. Previous studies have confirmed systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) could predict the prognosis of cancer patients. The aim of this study was to evaluate the pre-treatment SII and PNI in predicting outcomes in different cancers.</p><p><strong>Methods: </strong>The retrospective study included 508 cancer cases diagnosed between June 2013 and June 2022. The pre-treatment SII and PNI were calculated from peripheral blood samples, and the cutoff value was determined by receiver operating characteristic (ROC). The association of SII, PNI with clinicopathological characters and prognosis were assessed by Cox regression and Kaplan-Meier methods.</p><p><strong>Results: </strong>The ideal preoperative SII and PNI cutoff values were 792.0 and 49.825, respectively. High SII group as well as low PNI group had worse prognosis. Patients satisfied both high SII and low PNI had the lowest overall survival (OS) rate (<i>p</i> < 0.001). Multivariable Cox regression analysis identified that the tumor stage (<i>p</i> < 0.001), BMI (<i>p</i> = 0.042), SII (<i>p</i> = 0.001) and AGR (<i>p</i> = 0.047) were independently prognostic markers for OS.</p><p><strong>Conclusion: </strong>High level of pretreatment SII may be an independent prognostic factor for cancer patients. Patients with both high SII and low PNI had the worst prognosis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1351-1359"},"PeriodicalIF":2.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory Role and Mechanism of lncRNA RNF217-AS1 in the Proliferation and Migration of Esophageal Cancer Cells.","authors":"Jie Liang, Xiaoli Niu, Gaoyan Wang, Minghui Wang","doi":"10.2147/CMAR.S515036","DOIUrl":"10.2147/CMAR.S515036","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the effect of the long non-coding RNA (lncRNA) RNF217-AS1 on the proliferation and migration of esophageal cancer cells, and to uncover the molecular mechanisms through which RNF217-AS1 regulates these processes.</p><p><strong>Methods: </strong>The expression of RNF217-AS1 was measured in esophageal cancer cell lines (EC9706, Ecal09, KYSE-510, and TE-13) and immortalized esophageal epithelial HET-1 A cells using RT-qPCR. KYSE-510 cells were transfected with si-NC or si-RNF217-AS1 plasmids. Colony formation assays were used to assess cell proliferation, while migration ability was evaluated using scratch assays. A dual-luciferase reporter system was employed to verify the interaction between RNF217-AS1 and miR-377-3p. The expression of miR-377-3p and key proteins related to cell migration and epithelial-to-mesenchymal transition (EMT) were detected by RT-qPCR and Western blot.</p><p><strong>Results: </strong>RNF217-AS1 expression was significantly upregulated in esophageal cancer cells compared to HET-1 A cells (P<0.01). Downregulation of RNF217-AS1 in KYSE-510 and Eca109 cells led to a reduction in cell proliferation and migration (P<0.01). The dual-luciferase assay confirmed the interaction between RNF217-AS1 and miR-377-3p (P<0.01). miR-377-3p expression was elevated in the si-RNF217-AS1 group compared to the si-NC group (P<0.01). Furthermore, the protein levels of HOXA1, fibronectin, and FOXC2 were downregulated, while GRHL2 and E-cadherin expressions were increased in the si-RNF217-AS1 group (P<0.01).</p><p><strong>Conclusion: </strong>RNF217-AS1 is upregulated in esophageal cancer cells, and its downregulation inhibits the proliferation, migration and EMT of esophageal cancer cells by regulating the miR-377-3p/HOXA1 axis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1329-1337"},"PeriodicalIF":2.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway [Retraction].","authors":"","doi":"10.2147/CMAR.S551287","DOIUrl":"https://doi.org/10.2147/CMAR.S551287","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/CMAR.S261182.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1313-1314"},"PeriodicalIF":2.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}